PENNSYLVANIA, NEW YORK, and
WISCONSIN, May 21, 2024
/PRNewswire/ -- Today, 20/15 Visioneers, a leading advanced
science and technology management consulting and marketing services
company along with Quine Biologics Inc., and StableBody
Technologies LLC, leaders in Structure-based de-novo antibody
design and experts in Rational Protein Design, is pleased to
announce the collaboration and partnership to produce Next
Generation Rational Protein Design for the North American and
European markets.
In the rapidly evolving field of immunotherapy, vaccine
development, and diagnostics, the precision design of antibody
sequences to target specific epitopes by using three-dimensional
(3D) structures is at the forefront of scientific innovation.
Harnessing intricate 3D structural insights enables research
scientists to meticulously identify and modify key amino acid
residues. Consequently, amino acids sequences can be rationally
optimized for enhanced therapeutic efficacy and minimized
off-target effects.
In addition, enhancing antibody thermal stability influences
further antibody efficacy and applicability in manufacturing,
distribution, and administration processes. Highly stable
antibodies are paramount in targeted disease treatments, allowing
for the development of antibody-based therapies that retain
therapeutic efficacy over time. In diagnostic applications,
antibody stability is essential for ensuring reliable and
consistent test results, crucial for accurate disease detection,
and ensuring such biologics effectively meet modern medicine and
public health demands.
Quine Biologics is an expert in structure-based de-novo
antibody design therapies that retain therapeutic efficacy over
time. The Bespoke-A.B. design platform that focuses on protein
structure, automates and identifies the selection of antibody CDR
sequences and conformations. The technology uses a denoising
diffusion deep learning model resulting in a modeled 3D structural
representation of the novel antibody-antigen complex. The
technology creates new levels of unmatched specificity and high
affinity for the antibody-antigen interaction. This result heralds
a new era of tailored therapeutic and diagnostic agents.
StableBody Technologies is an expert in antibody
thermodynamic stabilization and affinity optimization. The
AffiBioTM software application optimizes recombinant
scFv characteristics such as stability, affinity, solubility, and
aggregation through the identification of amino acid positions
targeted for modifications is guided by the evolutionary responses
observed in protein databases. The StableBody Technologies
approach to protein stabilization improvements is heuristic in
nature, meaning StableBody Technologies its data builds on itself
and significantly reduces design work.
Protein primary sequences, their secondary structure
information, and the numerous variants found within various protein
databases serve as guides representing alternative protein folding
solutions. Previous studies have shown that some amino acid
sequence variations seen in these domains destabilize the tertiary
structure and other amino acid variations in the same sequence
compensate by increasing stability. This sequence variation is used
to rapidly search and identify the specific amino acid sites that
may exert influence on tertiary structure stability.
The collaboration project will create Next Generation Stable
Protein Reagents by:
(a) Improving the binding Kd by up to 300% for higher
sensitivity and reduce reagent usage; and
(b) Improving stability properties, conferring longer shelf
life, allowing for increased working temperatures by up 25%, and
eliminating cold chain issues for shipping and storage.
(c) Improving production efficiencies for reduced costs and time
to market.
About 20/15 Visioneers
Based on over 30 years of
experience, 20/15 Visioneers takes a holistic approach to
scientific management consulting as we focus on Culture,
Technology, Data, and Process. With our deep understanding of
scientific informatics, we can "Visioneer" next-generation
solutions and approaches that value scientific data-as-a-top asset
and prepare the organizations
for insilico-first (AI) approaches to
R&D. Our client base includes early to late research and
development, clinical, healthcare, materials science and
agriscience. Please get in touch with John F. Conway
from www.20visioneers15.com for more
information.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/quine-biologics-stablebody-technologies-and-2015-visioneers-announce-north-american-and-european-strategic-go-to-market-partnership-for-holistic-rational-protein-design-aiml-driven-lab-validated-302151533.html
SOURCE 20/15 Visioneers